Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thetideisturning ...
Crap shoot hmmmmmm ......
I no longer think so .......
JMHO, I BELIEVE we are in trader country ......
Noth'n more Noth'n less ........
I do see a BULL cycle though ......
WE ARE IN THE BULLS EYE --- GEO
Easyman ......
The "toe stepper" .......
always puts the "ship" in a vertical direction ......
and "never" sees it going horizontal .......
He will "yell" JUMP ........
rather than "jump on" ........
to much time is spent .......
discussing the "nays" .......
rather than the "yays" ......
Yes, this board is for discussion ........
but to often it is used to "plant fear and doubt" ......
WHICH IS REALLY TO BAD --- GEO
Easyman? .....
You said ...
"Oh, yes, this is for frogdreaming. Your opinion is also appreciated, as you have presented your opinion in an honorable fashion and for the most part keep the personal insults to the minimum, even though your possition here is an inigma. Peace."
Let me be clear here .......
frogdreaming or "little green devil" (more fitting) ......
has done nothing but provide misinformation .......
not JMHO but FACT .......
his motives are not seen by me, as honourable .....
but more on the distructive side .......
BEST TO THE LONGS AND HAPPY NEW YEAR --- GEO
Hopeless .....
for one I can read .......
and the second reason is ......(as my daughter would say)
JUST BECAUSE --- GEO (that should send you ranting and raving)
Hopeless ......
Are you involved in this convo? .......
You are smoking something come on, admit it ......
You have a chance here to buy Shares for pennies ......
quit fighting it and just buy like the rest of us .....
quit playing your games .......
and yes I am an idiot (for having this convo with you) .....
so in closing ......
GET LOST --- GEO
Hopeless .....
try and keep up ......
you are on the wrong page .......
perhaps you should go back and read it again .....
it is refering to a project ......
that is implemented by both DNAG and Moffitt ......
it involves XELOX and XELIRI ........
MERRY CHRISTMAS TO THE STAFF OF DNAG --- GEO
Hopeless .....
you get the BOOT minus the STOCKING ......
DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
SARASOTA, Florida, March 29, 2004/PRNewswire/ -- DNAPrint genomics (OTCBB: DNAP, the “Company”) of Sarasota, FL today announces that it has formed a multi-faceted pharmacogenomics program with the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. The program will aim to develop and implement new clinical tests for predicting patient response to various cancer chemotherapies.
Moffitt physicians and scientists are teaming with DNAPrint to identify genetic variants that underlie poor patient response to various chemotherapies, and to implement new clinical tests at the Center combining these variants with other biomarkers from gene-expression, proteomics and epidemiological research. The aim of the tests will be to predict patient chemotherapy response from the DNA before the commencement of the chemotherapy, so that patients with a genetic proclivity for poor or non-response can be spared from exposure to ineffective therapy. With the newly signed agreement, both organizations have teamed to make an important stride towards their goal of enabling a more personalized, safe and effective modality of cancer treatment for our current generation of cancer patients.
The program is multi-faceted and presently defines study in several cancer areas and clinical programs. Research will draw from several ongoing clinical trials and epidemiology research projects underway at the Center. A primary area of focus for the program is colorectal cancer, where DNAPrint will work with primary investigator Dr. Timothy Yeatman, Moffitt’s Associate Center Director for Clinical Investigations. DNAPrint will implement its proprietary ADMIXMAP genetic discovery platform to define gene sequences predictive for response to two anti-cancer treatments, XELOX and XELIRI. Though representing current FDA-approved therapies for metastatic colon cancer, approximately 50% of patients fail to respond and given the poor prognosis associated with non-response, there is a dire need for tools capable of predicting response before hand. The study design will aim to first discover and then evaluate the predictive power of predictive Single Nucleotide Polymorphism (SNP) markers in tandem with biomarkers from gene expression chip and proteomics research currently under way at Moffitt. The first colon cancer study will involve 100 patients. Other phases of this particular project will permit a retrospective alignment of genetic risk and epidemiologic factors, and prospective evaluation of chemotherapy response prediction in the setting of GLP and FDA approved clinical trial setting.
Over all of the program areas, the collaboration will combine Moffitt oncologists, research scientists, mathematicians and software engineers with DNAPrint computer scientists, molecular biologists and population geneticists, and draw upon DNAPrint’s pharmaceutical, clinical and regulatory expertise. Moffitt will contribute gene expression and proteomics data resources currently in development and DNAPrint will contribute its ADMIXMAP platform and SNP analysis for mapping the genetic determinants of variable drug response by harnessing the power of human population genetic structure. ‘We have identified several clinical projects at the Moffitt that are of keen commercial and social interest,’ said Dr. Hector J. Gomez, MD, PhD, Chairman of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. ‘Each of these programs offers us the opportunity to advance cancer treatment in a significant way,’ he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.
Moffitt sees thousands of cancer patients each year, and ranks with M.D. Anderson (Univ. Texas), Johns Hopkins (Baltimore, MD) and Fred Hutchinson (Seattle, WA) as among the nation’s busiest and most prestigious cancer research centers. The center has established a domestic and international network of collaborating physicians to build patient registries and implement cutting-edge methods for reducing, treating or preventing the onset of cancer diseases.
“Moffitt scientists and physicians were impressed with DNAPrint’s ADMIXMAP approach for using a populations’ structure as a fuel for mapping drug response gene variants. We recognized its profound potential for contributing to the enhancement of cancer treatment”, said Moffitt’s Dr. Timothy Yeatman.
Dr. Tony Frudakis, the scientific leader of DNAPrint and founder says, ‘By virtue of its broad scope and scale, and given its clinical setting, this is by far the most exciting research and product development opportunity yet for our young company. Our goal is simple - to present the FDA with what we can do and to pave the way for our brand of personalized medicine as the gold standard for drug development and use.’ He added, ‘The signing of this deal illustrates Dr. Gomez’s regulatory experience and leadership in the clinical development and pharmaceutical product approval process. This is invaluable to us as a company, as he brings a real world experience to our development programs.’
IMAGINE 100 PATIENTS AND NOW WE GO THE PUBLIC IN FLORIDA --- GEO
A NR right now ....
would be nice ......
PROMOTION, PROGRESSION, PRESERVATION --- GEO
A long long time ago ......
DNAWITNESS front and center .......
understand the importance ......
http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/20051220/NEWS/512200330/-1/SPECIAL12
"FAIRLY EASILY " --- GEO
Stinkboy .....
you're wrong ......
Hopeless has been firing the cannon of misinformation ......
and you ride shot-gun .......
I'd say do your DD ........
but you have, and that is why you are here ......
WHAT A JOKE YOU TWO ARE --- GEO
I should add .....
Christmas is about .....
friends and frienships ......
Joy and togetherness ........
MERRY CHRISTMAS TO ALL-AND ALL A GOOD NIGHT --- GEO
It sure would be nice .....
If the Company gave us a Christmas present ......
You must admit .....
IT SURE WOULD BE NICE --- GEO
money4nothin .....
Sorry to hear you can't average down ......
NOW IS THE TIME --- GEO
Hopeless ......
have you ever gone to a garage sail ......
pick something up for pennies ........
and later found out it was worth ....
a lot lot lot more than you paid for it ......
and that is why I am HOLDING and BUYING the DEALS ......
This Company is going to be worth a Fortune .......
NO IFS ANDS OR BUTS --- GEO
Dr FUD & Hopeless ......
reach over your cubicles and give each other a KISS ......
We are under valued ........
do yourselves a favour and .....
HOLD AND BUY THE DEALS --- GEO
Money4nothin .....
Great DD ....
But I still contend that we will Not see another R/S .....
also I am really happy we don't have over a 1.5billion in OS .....
I am still excited about the future .....
and have increased my ownership of DNAG .......
this was possible because of the R/S ........
This is the time if you are long, to accumulate .......
As a long we have a great op to HOLD and BUY the DEALS ......
and truly put the OS in long time investors hands .....
THESE ARE MY THOUGHTS --- GEO
GCBR .....
We are undervalued ......
THATS WHATS GOING ON --- GEO
Hopeless ....
as you Know .....
management has aquired 45mil shares as of late ......
Ellipsis as well as Kennan where aqiured through Shares .....
These Shares were used to improve Share Holder Value ......
SHARE HOLDER VALUE WILL INCREASE --- GEO
money4nothin ....
I for one do not believe we will see another R/S ....
plain and simple .......
MERRY XMAS TO YOU AND YOUR FRIENDS --- GEO
little green devil .....
intent? ......
Do you think they will have Ovanome to market? .......
do you think they will have any of their other products that are in the pipeline to market? ...
besides DNAWITNES and ANCESTRYBYDNA? ......
Simple answer will do: YES or NO ......
NO GOOF-BALL ANSWER NEEDED --- GEO
I like this part Gcbr ....
Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.
HENCE --- DNAPRINT GENOMICS --- GEO
Hopeless ....
You are also not in line to make my investments .....
THANK GOD FOR THAT .... LOL --- GEO
Dr FUD .....
You are not in line to make my investments ....
THANK GOD FOR ME ... lol --- GEO
Hopeless ....
Ok a typo should have been azd103 ....
Happy now? ....
as far as your other misinformation please read ...
Alzheimer's Disease Program
AZD103 is a small molecule inhibitor of amyloid beta peptide aggregation which in animal models has been shown to prevent, reduce and reverse Alzheimer's disease processes such as amyloid beta load and loss of cognitive function. The pre-clinical development program for AZD103 is on schedule with manufacturing of GMP AZD103 underway. It is expected that an Investigational New Drug ("IND") submission for AZD103 and the commencement of a Phase I study in healthy volunteers will occur in the fourth quarter of 2005. In addition, the pre-clinical toxicity program required to enable a Phase II trial in Alzheimer's patients will begin in the fall of 2005 and is expected to be completed in the second quarter of 2006. Transition is developing AZD103 in partnership with Ellipsis Neurotherapeutics Inc.
And if you have anything further to question .......
please phone TTH for further updates .....
OH AND THEY EXPECT THAT THE $3 BILLION MARKET WILL ONLY EXPAND OVER THE MANY YEARS GOING FORWARD --- GEO
Dr FUD .....
BLA BLA BLA ......
And you stay because? .......
DON'T INSULT ME WITH SOME GOOF-BALL ANSWER --- GEO
Monday Morning .....
and the 3 Bashers start the day .... lol
Lets start by saying 50/50 with regards to AZD105 ......
phase 11 ends second quarter of 2006 ......
$3 billion potential market ......
As far as Share Price? .....
why are we only at .02? .......
well you three ding dongs .....
sure throw out a lot of misinformation .......
and I believe JMHO .....
are trading the Share Price Down .......
My guess is only to accumulate more ........
or you have a sinister plan .......
you have to start somewhere .... lol
The closer we get to our goals the better ......
We are way under valued ......
So I plan to add more and more when I can .......
because the day will come .....
when the "bag" over other investors heads ......
will be knocked off, and the profound potential is seen ......
I am not worried and can only thank GOD ........
for allowing me to have found this Company .....
this gentleman ( I use the term loosely ) .....
is only the start of what this Company is capable of doing ....
as you have noticed of late though .......
as I am sure you have .....
the well is drying up ......
and investors have seen the pattern .......
so they HOLD and WAIT for the DEALS ......
Accumulation is the KEY as well as HOLDING ......
and you 3 ding dongs are going to get caught flat footed one day .....
The K report estimated a Share Price of $.45 ......
using an unbias means to achieve this number ....
also they predicted a Share price of $45 long term .....
this was done before the M&A with Ellipsis .....
which in turn gives us "the Share Holders" .....
an entry into a $3 billion market .......
so you can well imagine that our current Share Price is .....
"screaming" under valued .....
JMHO I don't think for long ........
at these Share Prices I am Holding and buying the deals .....
Soooo you bashers keep accumlating and dumping short term .....
and we longs will Hold and accumulate long term .......
and just so you know .....
Profits from my other investments .....
go straight into this investment .......
this is not a $.02 cent Company ......
so in turn this is an ideal time to invest ......
2006 ahhhh yes ......
2006 --- GEO
Sorry Gratli .....
after further review ......
the question should have been .....
what is half of $3 billion .......
the answer, still stands .......
A WHOLE LOT --- GEO
RECENT PUBLICATIONS: BY Mark Shriver
Shriver, M.D., Smith, M.W., Jin, L., Marcini, A., Akey, J.M., Deka, R., Ferrell, R.E. Ethnic affiliation estimation using population-specific DNA markers. in press (1997) Am J Hum Genet 60: 957-964.
MacHugh, D.E., Shriver, M.D., Loftus, R.T., Cunningham, P., and Bradley, D.G. (1997) Evolution, domestication and gene flow revealed with polymorphic microsatellites. Genetics 46: 1071-1086.
Shriver, M.D., Jin, L., Ferrell, R.E., Deka, R. (1997) Microsatellite data support an earlier population expansion in Africa. Genome Res 7: 586-591.
Shriver, M.D., Ethnic variation as a key to the biology of human disease. (1997) Annals of Internal Medicine 127: 401-304.
Shriver, S.P., Shriver, M.D., Tirpak, D.L., Bloch, L.M., Hunt, J.D., Ferrell, R.E., Siegfried, J.M. (1998) Trinucleotide reepeat length variation in the human ribosomal Protein L14 gene (RPL14): Localization to 3p21.3 and loss of heterozygosity in lung and oral cancers. Mutation Res. Genomics 406:9-23.
Parra, E., Marcini, A., Akey, J., Martinson, J., Batzer, M., Cooper, R., Forrester, T., Allison, D.B., Deka, R., Ferrell, R.E., Shriver, M.D. (1998) Estimating African-American Admixture Proportions by use of Population-Specific Alleles Am. J. Hum. Genet. 63:1839-1851.
HE KNOWS HIS STUFF --- GEO
This is great ......
but I can't find refrences to the first collaberation .....
Can any one help? ...
A GOOD READ .....
SARASOTA, FL AND OCEANSIDE, CA, Nov 14, 2005 (MARKET WIRE via COMTEX) --
DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative's extensive network of physician-managed centers with DNAPrint's proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."
"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."
This marks the second collaborative project between DNAPrint and Genetics Collaborative.
TWO COLLABORATIVE PROJECTS WITH SERACARE (very interesting) --- GEO
Here is some more DD Gratli ......
DNAPrint genomics to Acquire Ellipsis Biotherapeutics
Compatible Technologies Target Development Drugs for Personalized Medicine
SARASOTA, FL -- (MARKET WIRE) -- 11/15/2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has entered into an agreement to acquire the clinical genomics and genotyping assets of Ellipsis Biotherapeutics Corporation ("Ellipsis"), a privately held drug and diagnostic discovery company based in Toronto, Canada.
Under terms of the agreement, Ellipsis is selling these core assets for 6,500,000 shares of DNAPrint genomics common stock. Pending completion of DNAPrint due diligence and Ellipsis shareholder approval, the transaction is expected to be completed by Nov. 30, 2005. DNAPrint will retain Ellipsis' employees, management and business operations. In addition, DNAPrint will retain the Ellipsis Biotherapeutics name and operate Ellipsis Biotherapeutics as a subsidiary of DNAPrint genomics.
"Ellipsis has developed novel drug technologies and has spun those operations out," stated Hector J. Gomez, M.D., Ph.D., DNAPrint Chairman and Chief Medical Officer and head of its wholly owned DNAPrint Pharmaceuticals, Inc. subsidiary. "The value for DNAPrint is that Ellipsis' platform technology is highly compatible with our mission to expand our capabilities and increase our revenues."
Richard Gabriel, DNAPrint President and Chief Executive Officer, noted that DNAPrint is actively involved in development of pharmacogenomics through in-house research, licensing agreements and the acquisition of synergistic technologies, all targeting future growth for the Company. "Our recent acquisition of Kenna Technologies, which builds computer models that mimic complex biological systems, as well as Ellipsis' synergistic gene platform applications, will broaden our capabilities and add to the growing number of products in our pipeline."
PRETTY SIMPLE, PRETTY PROFITABLE --- GEO
Here is some DD Gratli1028 ....I LIKE!!! ..
Alzheimer's Disease Program
AZD103 is a small molecule inhibitor of amyloid beta peptide aggregation which in animal models has been shown to prevent, reduce and reverse Alzheimer's disease processes such as amyloid beta load and loss of cognitive function. The pre-clinical development program for AZD103 is on schedule with manufacturing of GMP AZD103 underway. It is expected that an Investigational New Drug ("IND") submission for AZD103 and the commencement of a Phase I study in healthy volunteers will occur in the fourth quarter of 2005. In addition, the pre-clinical toxicity program required to enable a Phase II trial in Alzheimer's patients will begin in the fall of 2005 and is expected to be completed in the second quarter of 2006. Transition is developing AZD103 in partnership with Ellipsis Neurotherapeutics Inc.
WHAT'S HAVE OF A BILLION? --- GEO
I Fear ......
There are no more deals JMHO .......
RESULTS DRIVEN, JMHO --- GEO
Keep your eye on the Ball ....
Effective April 4, 2005, we entered into a license agreement with Beth Israel
Deaconess Medical Center("Beth Israel"), a Massachusetts nonprofit corporation
to develop a new, more potent and longer acting form of the anemia drug
Erythropoietin ("EPO").
EPO is a glycoprotein naturally made by the body to stimulate red blood cell
production; the currently marketed forms are manufactured using recombinant DNA
technology and are used to treat anemia or low blood cell count. Under the
Agreement, Beth Israel has granted us an exclusive license to United States and
foreign patents related to certain forms of EPO. We have the right to develop,
use, market and sell products derived from the licensed patents.
In exchange for the license, we paid Beth Israel a $25,000 signing fee and
agreed to make certain milestone payments linked to their progress in developing
marketable products from the licensed technology. The total of payments, if all
milestones are reached, is $2,150,000. The milestone payments are nonrefundable.
Up to $200,000 of this amount is creditable against future royalties. In
addition to the milestone payments, we must also pay Beth Israel an annual
royalty of 4% of the net sales of all products developed from the licensed
technology. A minimum royalty payment of $100,000 a year is due upon the
commencement of commercial sales in any territory worldwide. At September 30,
2005, we had recorded the $25,000 as research and development costs.
Consulting Agreement with Dr. Arthur Sytkowski
On June 7, 2005, we entered into a consulting agreement with Dr. Arthur
Sytkowski, the Director of Beth Israel to consult on the development of a new,
more potent and longer acting form of EPO. On September 1, 2005, we entered into
a new consulting agreement amending and restating the June 7, 2005 consulting
agreement with Dr. Arthur Sytkowski. Under the amended consulting agreement, Dr.
Sytkowski has agreed to perform certain consulting services, including advising
on medical, regulatory and patent issues, training personnel and providing
assistance with EPO research and development. In exchange for the services, we
will pay Dr. Sytkowski $10,000 a month for twelve months, five annual incentive
payments of $25,000 each and certain milestone payments linked to our progress
under the Beth Israel license in developing marketable products from the
licensed EPO technology. The total of all payments to Dr. Sytkowski under the
agreement, assuming all milestones are reached, is $370,000. The milestone
payments will be reduced - dollar for dollar - to the extent Dr. Sytkowski
receives payments from Beth Israel relating to the same milestone events under
the Beth Israel license. At September 30, 2005, we had recorded $40,000 as
research and development costs.
Collaborative Research Agreement with Beth Israel
During late June, we entered into a collaborative research agreement with Beth
Israel to provide three researchers to us to conduct certain research work
related to our EPO research. On August 15, 2005, this agreement was amended. The
total cost per the amended agreement is $352,192. We have paid $176,096 and the
remaining $176,096 will be due 180 days after the execution of the amendment.
Consultant Agreement with Member of Our Scientific Advisory Board
During May 2005, we entered into a one-year agreement with our Scientific
Advisory Board member, to continue collaboration with us to develop commercial
tests for genetic ancestry and particular physical phenotypes. We have agreed to
compensate this consultant with quarterly payments of $4,000 and 2,500 shares of
our common stock. The term of this agreement is one year with automatic renewals
each year unless either party provides written notice of its intent not to renew
within thirty days prior to the annual anniversaries of this agreement. During
May 2005, we also entered into a license agreement with this consultant. This
license will remain in force in perpetuity as long as we are not in default of
the agreement. We agreed to provide the consultant with a number of shares of
our common stock equal to 2.5% of the net revenues derived from a product and
any subsequent versions of the products developed with his help.
CAN YOU AFFORD TO WAIT? ..... I CAN --- GEO
Hopeless .....
I guess they are going for the lunch ....LOL
Remember, IBM and National Geographics ......
interest in the ANESTRY PROJECT? .......
There is a interest in ANCESTRY! ......
We have to Market ANCESTRYBYDNA ......
with radio ads in NY ........
I expect more across the Country ......
perhaps another Country or 2? .......
WE HAVE AFTER YEARS OF RD JUST BEGUN --- GEO
Never Heard? .....
You usually don't here about something ....
until after the fact ........
so in fact, we should here after ......
Many Fronts on-going, in the last few months .....
This Company is a ......
BEJESUS GOLD MINE (JMHO) --- GEO
Dr Fud .....
you're thoughts .....
Once again Very misleading .......
you put the past into a relationship towards the future ....
the future is why I have stayed the course ......
do I see another R/S in the future .....
NOT A CHANCE (jmho) ......
Do I forsee advanced revenue in the future? .......
All signs say yes ......
PLEASE reflect on this issue DR FUD .......
would not a higher SP have a some what ......
NEGATIVE position on Dilution .......
so you understand what I'm saying ........
The higher the SP the LOWER the dilution ......
if dilution is used to increase Share holder Value .....
this is in the interest, to all investors going forward JMHO ........
I for one would like to see you removed from this board .....
but if you are sincere in your quest for fairness .....
you should remove yourself ......
I have never seen you post a "WHY" you have invested here ...
I have only seen you "why you shouldn't" .......
as far as why you should invest? ......
do your DD with some positive insight .......
There is gold in the ground .....
and DNAG is standing on top of it ........
Sooooo ........
going forward ......
next year looks great! .......
next year starts in 2 weeks .......
start of Q1 2006 starts in 2 weeks ........
as Baden Powell says ......
be prepared .......
PROFOUND POTENTIAL --- GEO (as said by Timothy Yeatman)
Butt frogdreaming ..... eom
I am Here ......
to participate in DNAG eventual triumph .......
investors like numbers .......
I am investing because .......
I believe DNAG will show excellent numbers ......
time and time again .......
This is a LONG term investment for me .......
and I (jmho) will see great strides forward .......
Quarter after Quarter ......
Everything lately has been done for a reason .....
I don't yet know why ......
but anticipate over time ......
I will be able to see clearly .........
All the best to everyone .......
And ....
MERRY CHRISTMAS AND A VERY HAPPY NEW YEAR --- GEO
Biofrontera ....
How are their convertable Bonds doing? ......
http://www.biofrontera.com/IR/wsv.html
IPO in April will be nice ......
OH, OH IT'S MAGIC --- GEO (yummy)
Nice Find Virgil .......
This statement is very much in favour for me .....
Cheng and his colleagues say this information could be useful for studying skin cancer, or for finding new ways of changing skin color that wouldn’t be as damaging as tanning.
IS THERE MONEY IN VANITY .... LOL --- GEO (incredible)